Innovative Gene-Edited Immune Cells Pave the Way for Universal 'Off-the-Shelf' Cancer Treatments
Scientists have developed a universal, off-the-shelf CAR-T cell therapy using gene editing to enhance immune evasion, promising faster and more accessible cancer treatment options.
Researchers at Peking University have made a significant breakthrough in cancer immunotherapy by developing a universal, ready-to-use treatment option. Led by Professor Wei Wensheng and in collaboration with the PLA General Hospital and biotech firm EdiGene Inc., the team has engineered a form of CAR-T cell therapy that can be administered to any patient without the need for custom preparation. This groundbreaking approach could dramatically increase accessibility and reduce costs associated with traditional CAR-T therapies.
CAR-T therapy, which involves reprogramming a patient's own immune cells to target cancer, has shown remarkable success against certain blood cancers like leukemia and lymphoma. However, its application has been limited due to the lengthy, expensive, and personalized manufacturing process, as well as challenges related to immune rejection when using donor cells.
To overcome these obstacles, the scientists focused on modifying donor CAR-T cells by removing a specific gene that acts as a marker for immune rejection. They then applied a glycan shielding technique, which adds a protective coating to the cells, allowing them to evade the host’s immune defenses. This 'armor' ensures the donor cells can survive longer within the patient's body.
Laboratory tests and initial patient trials demonstrated that these gene-edited, 'shielded' CAR-T cells maintain comparable cancer-killing effectiveness to traditional CAR-T cells. Importantly, they exhibited a longer persistence in the body without triggering severe side effects, showcasing their safety and potential as a universal therapy.
This innovative approach signifies a major step toward creating off-the-shelf CAR-T treatments that are quicker to deploy, more affordable, and widely available, offering renewed hope for cancer patients who previously lacked options. If further clinical trials confirm these findings, it could revolutionize cancer immunotherapy by making life-saving treatments accessible to all.
For more details, see the original study published in "Cell": Zeguang Wu et al, Glycan shielding enables TCR-sufficient allogeneic CAR-T therapy, 2025. DOI: 10.1016/j.cell.2025.07.046
Source: https://medicalxpress.com/news/2025-09-gene-immune-cells-universal-shelf.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Researchers Uncover Protective Kidney RNA with Potential to Revolutionize Disease Treatments
Scientists have identified a stress-responsive small RNA from transfer RNA that protects kidney cells and offers new potential for treating kidney diseases.
Innovative Engineered Antibodies Enable T-Cells to Target and Destroy Cytomegalovirus-Infected Cells
Researchers have engineered bispecific antibodies that direct T-cells to effectively target and eliminate cytomegalovirus-infected cells, offering new hope for immunocompromised patients battling CMV infections.
The Role of Cellular Antennas in Regulating Fat Cell Development and Obesity Prevention
New research highlights the vital role of primary cilia in fat tissue development and obesity prevention through signaling pathway regulation.
Boehringer Ingelheim Receives U.S. Approval for Innovative Lung Cancer Treatment
Boehringer Ingelheim has received FDA approval for zongertinib, a new oral treatment for HER2-mutant non-small cell lung cancer, offering hope for patients with limited options.